SLV-213 is under clinical development by Selva Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SLV-213’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SLV-213 overview
SLV-213 is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Ebola virus, Nipah viruses, Marburg viruses and Chagas disease. It is administered through oral route in the form of tablet. The drug candidate acts by inhibiting cathepsin L.
Selva Therapeutics overview
Selva Therapeutics biotechnology company that develops drugs targeting infectious diseases. It is investigating its lead product candidate SLV213, a small molecule antiviral oral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The company is also evaluating SLV213 against Chagas disease, Ebola, Nipah, and other paramyxoviruses. Selva Therapeutics is headquartered in Del Mar, California, the US.
For a complete picture of SLV-213’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.